APMAdvances in Precision Medicine2424-85922424-9106WHIOCE PUBLISHING PTE. LTD.10.18063/APM.v11i4.1863ArticleEffects of Sevoflurane on NGAL and MCP-1 Expression in the Kidneys of Diabetic Nephropathy Micehttps://artdesignp.com/journal/APM/11/4/10.18063/APM.v11i4.1863TanHongjing,YaoHong’ai,WangBo,YangJiao,ZhaoYi,LuoKai20261142026-04-26Objective: To investigate whether AS1842856 can modulate the protective effect of sevoflurane on ischemia-reperfusion injury (IRI) in diabetic nephropathy (DN) mice. Methods: Forty DN mouse models were prepared and randomly divided into the sham operation group (Sham group), renal ischemia-reperfusion group (I group), sevoflurane group (S group), and AS1842856 group (AS group), with 10 mice in each group. The I group underwent IRI model establishment; the Sham group did not receive renal pedicle occlusion, the S group received sevoflurane pretreatment before IRI model establishment, and the AS group received AS1842856 solution via gastric administration prior to sevoflurane treatment and IRI model establishment. The conditions of all groups were compared. Results: Compared with the I group, mice in the AS group exhibited improved general condition, reduced serum creatinine and blood urea nitrogen levels (P < 0.05), milder renal injury as shown by hematoxylin-eosin staining, and decreased expression of neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemoattractant protein-1 (MCP-1) proteins and their mRNA levels (P < 0.05). Conclusion: Sevoflurane pretreatment abolishes its protective effect against IRI in DN mice, whereas AS1842856 can modulate the protective effect of sevoflurane on IRI in DN mice.Diabetic nephropathy,Ischemia-reperfusion injury,Sevoflurane,Forkhead box transcription factor O1 (FOXO1),AS1842856

[1] Samsu N, 2021, Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int, 2021: 1497449. [2] Sperna Weiland NH, Hermanides J, van der Ster BJP, et al., 2018, Sevoflurane Based Anaesthesia Does Not Affect Already Impaired Cerebral Autoregulation in Patients with Type 2 Diabetes Mellitus. Br J Anaesth, 121(6): 1298–1307. [3] Li X, Lü Q, Wu QY, et al., 2022, Study on the Establishment of a Diabetic Nephropathy Model in C57Bl/6J Mice Using a High-Fat and High-Sugar Diet Combined with STZ. Chongqing Medical Journal, 51(1): 16–19. [4] Guan Y, Li L, Tian Y, 2021, The Protective Effect of Ischemia Preconditioning on Renal Ischemia-Reperfusion Injury in Mice. Journal of Clinical and Experimental Medicine, 20(13): 1345–1348. [5] Zhang L, Zhan QH, Chen J, et al., 2016, Protective Effect of Sevoflurane Pretreatment in Renal Ischemia-Reperfusion. Journal of Practical Medicine, 32(22): 3669–3672. [6] Lin HB, Chen Y, Shen P, et al., 2018, Incidence and Risk Factors of Chronic Kidney Disease among Community-Based Diabetic Patients. Journal of Peking University (Medical Edition), 50(3): 416–421. [7] Liu C, Shen Z, Liu Y, et al., 2015, Sevoflurane Protects Against Intestinal Ischemia-Reperfusion Injury Partly by Phosphatidylinositol 3 Kinases/Akt Pathway in Rats. Surgery, 157(5): 924–933. [8] Lin A, Piao HL, Zhuang L, et al., 2014, FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K-AKT Pathway. Cancer Res, 74(6): 1682–1693. [9] Huang YJ, Zhang WX, Ding ZB, et al., 2019, FoxO1 Inhibitor AS1842856 Reverses Depression-Like Behaviors Induced by High-Fat Diet in Mice. China Journal of Drug Dependence, 28(6): 426–431, 455. [10] Li M, Wang LL, Cen LH, et al., 2020. Study on the impact of the Forkhead Box Family Transcription Factor O1 Inhibitor on the Protective Effect of Sevoflurane Against Renal Ischemia-Reperfusion Injury in Diabetic Mice. China Journal of Diabetes, 28(7): 537–543.